|
|
The company expects to receive a limited trial protocol from FDA for the final approval of its drug Surfaxin. The drug was supposed to be approved long time ago. Both safety and efficacy were demonstrated. However, the company has had difficulties to get the stability problem solved.
Short-term upside potential $1.65-$2, downside $0.35. Only bet with the money you can afford to lose. Good Luck. |
|
狗仔卡
发表于 2010-1-11 03:37 AM
提升卡
置顶卡
沉默卡
喧嚣卡
变色卡